Companies › Axsome Therapeutics
3 active drug programs in 16 registered trials: 10 Phase 3, 4 Phase 4, 2 Phase 2; Other, Psychiatry, Genitourinary, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bupropion (AXS-05) Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma … | Dec 2027 |
| Solriamfetol Dose A Dopamine and norepinephrine reuptake inhibitor | SLC6A3, SLC6A2 | Phase 3 | Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Dec 2026 |
| Esreboxetine (AXS-14) Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Fibromyalgia | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06223880 | Bupropion (AXS-05) | Phase 4 | Major Depressive Disorder | Psychiatry | Mar 2026 |
| NCT06568367 | Solriamfetol Dose A | Phase 3 | Excessive Sleepiness | Other | Dec 2026 |
| NCT06413433 | Solriamfetol Dose A | Phase 3 | Binge-Eating Disorder | Psychiatry | Dec 2026 |
| NCT06675851 | Bupropion (AXS-05) | Phase 4 | Major Depressive Disorder (MDD) | Psychiatry | Dec 2026 |
| NCT03996265 | Bupropion (AXS-05) | Phase 3 | Hematopoietic and Lymphatic System Neoplasm | Oncology | Dec 2026 |
| NCT07523048 | Bupropion (AXS-05) | Phase 2 | Major Depressive Disorder (MDD) | Psychiatry | Jan 2027 |
| NCT05732272 | Bupropion (AXS-05) | Phase 3 | Smoking Cessation | Other | Jan 2027 |
| NCT04422652 | Bupropion (AXS-05) | Phase 2 | Chronic Kidney Diseases | Genitourinary | Apr 2027 |
| NCT05273996 | Bupropion (AXS-05) | Phase 4 | Major Depressive Disorder | Psychiatry | Apr 2027 |
| NCT06233799 | Bupropion (AXS-05) | Phase 3 | Methamphetamine-dependence | Psychiatry | Apr 2027 |
| NCT07766655 | Bupropion (AXS-05) | Phase 3 | Smoking Cessation | Other | Dec 2027 |
| NCT07398417 | Esreboxetine (AXS-14) | Phase 3 | Fibromyalgia | Other | Mar 2028 |
| NCT07717879 | Solriamfetol Dose A | Phase 3 | ADHD | Psychiatry | Jun 2028 |
| NCT07717892 | Solriamfetol Dose A | Phase 3 | ADHD | Psychiatry | Jun 2028 |
| NCT07484217 | Solriamfetol Dose A | Phase 3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Psychiatry | Dec 2028 |
| NCT04604509 | Bupropion (AXS-05) | Phase 4 | Cigarette Smoking-Related Carcinoma | Oncology | Dec 2028 |
Cash of $314m on 2026-09-30; operating cash outflow about $85m a year; runway about 44 months at that burn, to Jun 2030; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Primus Pharmaceuticals Palvella Therapeutics Definium Therapeutics US Adneuris Therapeutics Sound Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.